encik mohd izhar bin ariff

pegawai sains

jab perubatan, hukm

 izhar.ariff@ppukm.ukm.edu.my



   Biografi/ Biography :

  • PEGAWAI SAINS

  • adawiyah binti jamil;norazirah binti md nor;mohd izhar bin ariff;mohan a/l arumugam.  (2023).  m19-850: a phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in study m16-046.  -

     

    tan hj, ng cf, siti zaleha s, nursyazwana z, nurarifah mk, mohd izhar a, khoo cs.  (2021).  diagnosis of narcolepsy using the modified multiple sleep latency test.  - 1st malaysian epilepsy congress 2021.  61-62. 

     

    law zhe kang, tan hui jan, chin sze piaw, wong chee yin, wan nur nafisah wan yahya, ahmad sobri muda, rozman zakaria, mohd izhar ariff, nor azimah ismail, cheong soon keng, s fadilah a wahid, norlinah mohamed ibrahim.  (2021).  the effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and.  - cytotherapy.  833-840. 

     

    al-qazzaz n.k., ali s., ahmad s.a., islam m.s., ariff m.i..  (2015).  selection of mother wavelets thresholding methods in denoising multi-channel eeg signals during working memory task.  - iecbes 2014, conference proceedings - 2014 ieee conference on biomedical engineering and sciences: "miri, where engineering in medicine and biology and humanity meet".  214-219. 

     

    law zhe kang, tan hui jan, chin sze piaw, wong chee yin, wan nur nafisah wan yahya, ahmad sobri muda, rozman zakaria, mohd izhar ariff, nor azimah ismail, cheong soon keng, s fadilah a wahid, norlinah mohamed ibrahim.  (2021).  the effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and.  - cytotherapy.  833-840. 

     

    law zhe kang, tan hui jan, chin sze piaw, wong chee yin, wan nur nafisah wan yahya, ahmad sobri muda, rozman zakaria, mohd izhar ariff, nor azimah ismail, cheong soon keng, s fadilah a wahid, norlinah mohamed ibrahim.  (2021).  the effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and.  - cytotherapy.  833-840. 

     

    al-qazzaz n.k., ali s., ahmad s.a., islam m.s., ariff m.i..  (2015).  selection of mother wavelets thresholding methods in denoising multi-channel eeg signals during working memory task.  - iecbes 2014, conference proceedings - 2014 ieee conference on biomedical engineering and sciences: "miri, where engineering in medicine and biology and humanity meet".  214-219. 

     

    adawiyah binti jamil;norazirah binti md nor;mohd izhar bin ariff;mohan a/l arumugam.  (2023).  m19-850: a phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in study m16-046.  -

     
    Geran / Grant Kolaborator / Collaborator Status
    A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NOT PREVIOUSLY TREATED WITH COMPLE f. hoffmann-la roche ltd
    81% (2020-12-10 sehingga 2025-02-09)
    A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NOT PREVIOUSLY TREATED WITH COMPLE iqvia rds malaysia, sdn, bhd
    81% (2020-12-10 sehingga 2025-02-09)
    A RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED CARDIOVASCULAR DISEASE (VICTORION-2 PREVENT) novartis pharma ag
    44.5% (2023-06-06 sehingga 2025-06-05)
    A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF IANALUMAB (VAY736) VERSUS PLACEBO IN ADDITION TO FIRST-LINE CORTICOSTEROIDS IN PRIMARY IMMUNE THROMBOCYTOPENIA (VAYHIT1) novartis corporation (malaysia) sdn. bhd.
    9.8% (2023-10-09 sehingga 2029-05-08)
    A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF IANALUMAB (VAY736) VERSUS PLACEBO IN ADDITION TO ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WHO HAD AN INSUFFICIENT RESPONSE OR RELAPSED AFTER FIRST LINE STEROID TREATMENT (VAYHIT2) novartis corporation (malaysia) sdn. bhd.
    10.1% (2023-10-09 sehingga 2029-03-08)